FDA expands ImmunityBio's Anktiva label to papillary-only bladder cancer

Mugglehead
By Theo MarchettiOct 14, 2026, 4:07 pm76 pts
The U.S. Food and Drug Administration expanded Anktiva's bladder-cancer indication on Wednesday, Oct. 14, to include adults with BCG-unresponsive, high-grade papillary-only tumours. Evidence from 77 patients with carcinoma in situ supports the expanded label for ImmunityBio, Inc. (NASDAQ: IBRX). ImmunityBio…

Read Article Share
Share Article
- email
- x.com
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

THCA Flower Explained: The Chemistry Behind Cannabis Before Heating 79

FDA expands ImmunityBio's Anktiva label to papillary-only bladder cancer 76

As rescheduling fuels cannabis deals, integration decides who wins 69

DEA Registration for Certain Medical Cannabis Businesses Opens 69

Cannabis Rescheduling Process Remains Sidelined, DEA Judge Orders New Replies 66

States don’t need to change rules to comply with federal marijuana rescheduling 14

States don’t need to change rules to comply with federal marijuana rescheduling 7

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.